We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Company Acquisition to Ease Market Entry and Shorten Development Time for New Tests

By LabMedica International staff writers
Posted on 15 Sep 2015
Two North American manufacturers of rapid diagnostic tests are combining in order to pool their products for rapid entry into the diagnostic product market and to boost development of new tests.

NOWDiagnostics Inc. (Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada). NOWDiagnostics manufactures and sells a line of blood-based rapid tests that allow health care providers to conduct simple-to-use, highly accurate tests for a variety of ailments and diseases. ZBx Corporation, with a customer base that includes Canada, Europe, Asia, Africa, South America and Mexico, develops and manufactures rapid format, point-of-care diagnostic products in both the human and veterinary fields.

“We are excited about the growth of NOWDiagnostics and what this means for point-of-care testing and the healthcare industry in general. Our acquisition of ZBx, with its deep product portfolio, experienced personnel, and broad capabilities, will help us increase the speed at which we are currently developing our tests,” said Kevin Clark, CEO of NOWDiagnostics. “The tests we are creating have the potential to revolutionize current medical test protocols and to lower costs to insurance companies and, ultimately, consumers.”

Related Links:

NOWDiagnostics
ZBx Corporation


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
New
Electrolyte Analyzer
BKE-B

Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
ADLM